Suppr超能文献

估算澳大利亚因心脏康复参与度低而导致的健康损失。

Estimating the health loss due to poor engagement with cardiac rehabilitation in Australia.

作者信息

Driscoll A, Hinde S, Harrison A, Bojke L, Doherty P

机构信息

Deakin University, School of Nursing and Midwifery, 1 Gheringhap Street, Geelong, VIC 3220, Australia.; Austin Health, Dept of Cardiology, Studley Rd, Heidelberg, VIC 3081, Australia.

University of York, Centrefor Health Economics, Alcuin A Block, Heslington, York, YO105DD, UK.

出版信息

Int J Cardiol. 2020 Oct 15;317:7-12. doi: 10.1016/j.ijcard.2020.04.088. Epub 2020 May 3.

Abstract

BACKGROUND

Cardiac rehabilitation (CR) programs are effective in reducing cardiovascular mortality and readmissions. However, most patients are denied the benefits of CR due to low referral rates. Of those patients referred, commencement rates vary from 28.4% to 60%. This paper quantifies the scale of health loss in Australia due to poor engagement with the program, and estimates how much public funding can be justifiably reallocated to address the problem.

METHODS

Economic decision modelling was undertaken to estimate the expected lifetime health loss and costs to Medicare. Key parameters were derived from Australian databases, CR registries and meta-analyses. Population health gains associated with uptake rates of 60%, and 85% were calculated.

RESULTS

CR was associated with a 99.9% probability of being cost-effective, even at a cost-effectiveness threshold lower than conventionally applied. Importantly, an average of 0.52 years of life expectancy are lost due to national uptake being below 60% achieved in some best performing programs in Australia, equivalent to 0.28 quality adjusted life years. The analysis indicates that $12.9 million/year could be justifiably reallocated from public funds to achieve a national uptake rate of 60%, while maintaining cost-effectiveness of CR due to the large health gains that would be expected.

CONCLUSION

CR is a cost-effective service for patients with coronary heart disease. In Australia, less than a third of patients commence CR, potentially resulting in avoidable patient harm. Additional investment in CR is vital and should be a national priority as the health gains for patients far outweigh the costs.

摘要

背景

心脏康复(CR)项目在降低心血管疾病死亡率和再入院率方面具有显著效果。然而,由于转诊率较低,大多数患者无法从中受益。在那些被转诊的患者中,开始参与项目的比例从28.4%到60%不等。本文量化了澳大利亚因参与该项目不佳而导致的健康损失规模,并估计可以合理重新分配多少公共资金来解决这一问题。

方法

采用经济决策模型来估计预期的终身健康损失和医疗保险费用。关键参数来自澳大利亚数据库、CR登记处和荟萃分析。计算了与60%和85%的参与率相关的人群健康收益。

结果

即使在低于传统应用的成本效益阈值的情况下,CR具有成本效益的概率为99.9%。重要的是,由于澳大利亚一些表现最佳的项目中全国参与率低于60%,平均预期寿命损失0.52年,相当于0.28个质量调整生命年。分析表明,每年可以从公共资金中合理重新分配1290万美元,以实现全国60%的参与率,同时由于预期的巨大健康收益,保持CR的成本效益。

结论

CR对冠心病患者来说是一种具有成本效益的服务。在澳大利亚,不到三分之一的患者开始接受CR治疗,这可能导致可避免的患者伤害。对CR的额外投资至关重要,应成为国家优先事项,因为患者的健康收益远远超过成本。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验